Alterations in cell cholesterol content modulate Ca(2+)-induced tight junction assembly by MDCK cells.
Transepithelial electrical resistance (TER), a measure of tight junction (TJ) barrier function, develops more rapidly and reaches higher values after preincubation of MDCK cells for 24 h with 2 microM Lovastatin (lova), an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase. While this effect was attributed to a 30% fall in cholesterol (CH), possible effects of lova on the supply of prenyl group precursors could not be excluded. In the current study, strategies were devised to examine effects on TER of agents that simultaneously lower CH and increase the flux of intermediates through the CH biosynthetic pathway. Zaragozic acid, 20 microM, an inhibitor of squalene synthase known to increase the synthesis of isoprenoids and levels of prenylated proteins, lowered cell CH by 30% after 24 h, while accelerating development of TER in the same manner as lova. TER was also enhanced, despite a 23% increase in the rate of [3H]acetate incorporation into CH, when total CH was reduced by 45% during a 2-h incubation with 2 mM methyl beta-cyclodextrin (MBCD), an agent that stimulates CH efflux from cells. The fact that the rate of TER development was diminished when cell CH content was elevated by incubation with a complex of CH and MBCD is further evidence that this sterol modulates development of the epithelial barrier. Cell associated CH derived from the complex was similar to endogenous CH with respect to its accessibility to cholesterol oxidase. Lova's effect on TER was diminished when 5 micrograms/mL of CH was added to the medium during the last 11 h of incubation with lova.
Stankewich
M C
MC
Department of Biological Sciences, University of Massachusetts at Lowell 01854, USA.
Francis
S A
SA
Vu
Q U
QU
Schneeberger
E E
EE
Lynch
R D
RD
D000818:Animals; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology; D002118:Calcium / Q000494:pharmacology*; D002784:Cholesterol / Q000378:metabolism*; D002789:Cholesterol Oxidase / Q000378:metabolism; D003505:Cyclodextrins / Q000494:pharmacology; D004285:Dogs; D004791:Enzyme Inhibitors / Q000494:pharmacology; D013186:Farnesyl-Diphosphate Farnesyltransferase / Q000037:antagonists & inhibitors; D007668:Kidney / Q000648:ultrastructure; D008148:Lovastatin / Q000494:pharmacology; D019108:Tight Junctions / Q000187:drug effects*; D014233:Tricarboxylic Acids / Q000494:pharmacology; D047392:beta-Cyclodextrins
D019086:Bridged Bicyclo Compounds, Heterocyclic; D003505:Cyclodextrins; D004791:Enzyme Inhibitors; D014233:Tricarboxylic Acids; D047392:beta-Cyclodextrins; C075117:squalestatin 1; D002784:Cholesterol; D008148:Lovastatin; D002789:Cholesterol Oxidase; D013186:Farnesyl-Diphosphate Farnesyltransferase; C031215:betadex; D002118:Calcium